<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11859846</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.196</article-id><article-id pub-id-type="other">O0070</article-id><article-id pub-id-type="pii">S0924933824001962</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>Oral Communication</subject></subj-group></article-categories><title-group><article-title>Nicotinamide Riboside Attenuates Memory Impairment and Depressive-like Behavior in an Alzheimer&#x02019;s Disease Animal Model</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Aytulun</surname><given-names>A.</given-names></name><xref rid="aff0250" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor0057" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cimen</surname><given-names>B.</given-names></name><xref rid="aff0251" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sara</surname><given-names>Y.</given-names></name><xref rid="aff0251" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Erden Aki</surname><given-names>S. &#x000d6;.</given-names></name><xref rid="aff0252" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="aff0250"><sup>1</sup>Psychiatry, Kilis Prof Dr Alaeddin Yava&#x0015f;&#x000e7;a State Hospital, <city>Kilis</city></aff><aff id="aff0251"><sup>2</sup>Medical Pharmacology</aff><aff id="aff0252"><sup>3</sup>Psychiatry, <institution>Hacettepe University Faculty of Medicine</institution>, <city>Ankara</city>, <country>T&#x000fc;rkiye</country></aff><author-notes><corresp id="cor0057"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="171">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S73</fpage><lpage>S73</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824001962a.pdf"/><abstract><sec id="sec0339"><title>Introduction</title><p>Depression in Alzheimer&#x02019;s disease (AD) differs from major depression in terms of clinical features and treatment. Antidepressants do not provide the expected benefits in depressive symptoms accompanying cognitive decline in AD, suggesting distinct mechanisms. Emerging research suggest that compromised mitophagy, the selective removal of damaged mitochondria, may contribute to the pathogenesis of AD. However boosting nicotinamide adenine dinucleotide (NAD+) to induce mitophagy reduces amyloid &#x003b2; (A&#x003b2;) aggregation and enhances cognitive function in AD models (Kerr 
<italic toggle="yes">et al</italic>.,Trends Neurosci 2017;40:151-66). Nevertheless, data on NAD&#x02019;s impact on depression in AD remains limited.</p></sec><sec id="sec0340"><title>Objectives</title><p>This study aimed to examine the impact of the NAD+ precursor nicotinamide riboside (NR) on cognitive and neuropsychiatric symptoms in a AD rat model.</p></sec><sec id="sec0341"><title>Methods</title><p>To induce the AD, a single dose of 5 &#x003bc;l A&#x003b2;1-42 was injected into each lateral ventricle of rats (day 0), while the control group received an intracerebroventricular (icv) saline (0.9%NaCl).Four experimental groups were designed: control (icv saline+po saline), NR (icv saline+po NR), A&#x003b2; (icv A&#x003b2;+po saline), and A&#x003b2;+NR (icv A&#x003b2;+po NR).After the injection, to reduce A&#x003b2; clearance (Kang <italic toggle="yes">et al.</italic> Science. 2009;32 1005-7.) rats were subjected to 96 hours of sleep deprivation.Starting from day 6, rats were given either 700 mg/kg oral NR or saline, and handling test scores were recorded daily.The procedures were repeated daily until the rats were sacrificed on day 28.Behavioral experiments were randomly conducted at the end, and statistical analysis was performed using repeated measures ANOVA, followed by the Tukey post hoc test.</p></sec><sec id="sec0342"><title>Results</title><p>Passive avoidance test results showed that the A&#x003b2; group had the shortest latency to enter the dark area. However, the A&#x003b2;+NR group exhibited a prolonged latency compared to the A&#x003b2; group (F(3,2)=5.5;p&#x0003c;0.05). A&#x003b2; injection induced depressive-like behavior in rats, as indicated by the forced swim test (FST) for behavioral despair and the sucrose preference test (SPT) for anhedonia. In AD rats treated with NR (A&#x003b2;+NR), A&#x003b2;-induced depressive-like behavior was reduced, with lower FST immobility scores (F(3,2)=6.2;p&#x0003c;0.05) and increased sucrose preference in the SPT (F(3,2)=7.5;p&#x0003c;0.05). There were no significant differences in anxiety-like behaviors among the groups, assessed by the time spent in the open arm in the elevated plus maze test (F(3,2)=1.9;p&#x0003e;0.05). During the 28-day monitoring period, the A&#x003b2;+NR group of rats exhibited a more rapid decrease in aggression levels compared to the other groups in the handling test. This decrease was significant between days 7 and 10 compared to the A&#x003b2; group (F(48,5)=1.5;p&#x0003c;0.05).</p></sec><sec id="sec0343"><title>Conclusions</title><p>NR improved memory, reduced depressive behavior, and lowered aggression in AD rats. This suggests that&#x000a0;NAD+ precursor NR effectively treats cognitive decline and neuropsychiatric symptoms in an AD model.</p></sec><sec id="sec0344"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>